Carteolol HydrochlorideThird Party Manufacturing in India

Carteolol Hydrochloride works by blocking both beta-1 and beta-2 adrenergic receptors while exhibiting intrinsic sympathomimetic activity (ISA), which lowers intraocular pressure by reducing the secretion of aqueous humor in the ciliary body. It binds to these ocular receptors to help the body manage chronic pressure elevation. Unlike standard beta-blockers, its intrinsic sympathomimetic activity helps maintain basal blood flow to the optic nerve head and minimizes local irritation. It is highly effective and well-tolerated.

Therapeutic Uses

• Chronic Open-Angle Glaucoma: Prescribed to lower intraocular pressure in patients with open-angle glaucoma to prevent optic disc cupping.
• Ocular Hypertension: Indicated for managing elevated baseline intraocular pressures that threaten visual field integrity.

Why Manufacturers Choose Carteolol Hydrochloride

Carteolol Hydrochloride third party manufacturing in India serves an essential demographic of glaucoma patients who require beta-blocker therapy but suffer from local vascular vasospasms. Celesta coordinates sterile processing via established partner facilities that are WHO-GMP certified, assuring precise pH balancing and sterile liquid filling accuracy. Offering this advanced beta-blocker allows medical companies to round out their ophthalmology line with a high-compliance product backed by global WHO-GMP protocols.